Melanoma Dispatch
Follow
Find tag "S6"
2.0K views | +2 today
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

New Test May Reveal When Melanomas Resist Targeted Therapies

New Test May Reveal When Melanomas Resist Targeted Therapies | Melanoma Dispatch | Scoop.it

Melanomas with BRAF mutations often become drug-resistant, but now researchers think they know how to tell who will benefit from continued treatments. The researchers studied BRAF-mutant melanomas in nine people before and after targeted treatment, and found that tumors were less likely to grow when a protein called S6 was not activated. Next, the researchers developed a way to monitor S6 — and so tumor response —in treated melanomas in real-time. Their method entails fine-needle aspiration, which is far less invasive than conventional biopsies and could potentially replace the serial biopsies currently done to test for tumor resistance.

Cancer Commons's insight:

HemOnc Today │ Nov 11, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

New Test May Show When BRAF Inhibitors Work

New Test May Show When BRAF Inhibitors Work | Melanoma Dispatch | Scoop.it

Even though about half of melanomas have BRAF mutations, some of these still fail to respond to BRAF inhibitors. Now, there may be a way to tell whether BRAF inhibitors are working, according to findings presented at the 2013 International Conference on Molecular Targets and Cancer Therapeutics. The researchers found that a BRAF inhibitor kept tumors from growing in six out of nine people with BRAF-mutant melanomas, and that those who benefitted from the treatment also had less activation of a protein called S6 at 2 weeks. If this link is verified in large clinical trials, S6 activation levels could predict BRAF inhibitor effectiveness during the early stages of treatment.

Cancer Commons's insight:

American Association for Cancer Research | Oct 22, 2013

more...
No comment yet.